ProStrakan originally licensed the European rights to Rapinyl from Orexo AB in December 2005. ProStrakan expects to submit Rapinyl for marketing approval in Europe in 2006. Under the terms of the agreement, ProStrakan will receive advance payment plus approval and sales milestones, the press release said.
ProStrakan will retain responsibility for obtaining marketing approval for Rapinyl in each of the licensed territories and will supply Rapinyl at an agreed transfer price, while Richter will be responsible for obtaining pricing and reimbursement approvals. The two companies will collaborate on a marketing and launch plan for Rapinyl in these territories.
Rapinyl is a new, rapidly disintegrating, muco-adhesive sublingual tablet formulation of the opioid drug fentanyl, expected to be indicated for the management of breakthrough cancer pain.
